| Bioactivity | Avutometinib (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC)[1][2]. |
| CAS | 946128-90-1 |
| Formula | C21H18FKN5O5S |
| Molar Mass | 510.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. McNamara B, et al. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecol Oncol. 2024 Apr;183:133-140. [2]. Coma S, et al. Abstract A091: The RAF/MEK clamp avutometinib as the backbone of therapy for pancreatic cancer: Novel combinations with standard of care chemotherapy, FAK inhibitors, KRAS G12D inhibitors and/or autophagy inhibitors[J]. Cancer Research, 2024, 84(2_Supplement): A091-A091. |
Avutometinib potassium
CAS: 946128-90-1 F: C21H18FKN5O5S W: 510.56
Avutometinib (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.